Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11731931 | 0.88 | TAAR1 (0.54) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL19285690 | 0.86 | HTR2A (0.69) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL31455956 | 0.84 | TAAR1 (0.53) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL11739911 | 0.80 | TAAR1 (0.71) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL31498057 | 0.80 | TAAR1 (0.71) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL27878290 | 0.79 | TAAR1 (0.54) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL29279603 | 0.79 | TAAR1 (0.47) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL31456080 | 0.79 | HTR2A (0.52) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL31456000 | 0.78 | TAAR1 (0.50) | TAAR1HTR2A | |
| SCHEMBL29279530 | 0.78 | TAAR1 (0.46) | TAAR1HTR2AHTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2024073601-A2 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | ATXN2, HCRTR2, CDR2 | TAAR1 345/4885HTR2A 173/4885HTR1A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.